Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

The high frequency of RASSF1A methylation has been noted in a vast number of patients in a broad spectrum of malignancies, suggesting that RASSF1A inactivation is associated with cancer pathogenesis. However, whether this recurrent incidence of RASSF1A hypermethylation in human malignancies and its association with more aggressive tumour phenotype is a frequent event across different cancer types has not yet been discussed. In this review, we interrogated existing evidence for association of RASSF1A hypermethylation with clinicopathological characteristics that can indicate more invasive lesions.

Original publication

DOI

10.1038/bjc.2015.221

Type

Journal article

Journal

Br J Cancer

Publication Date

28/07/2015

Volume

113

Pages

372 - 381

Keywords

Biomarkers, Tumor, DNA Methylation, Gene Silencing, Humans, Neoplasm Invasiveness, Neoplasms, Predictive Value of Tests, Prognosis, Tumor Suppressor Proteins